Editor’s Note: In January of 2020, Verastem Oncology obtained worldwide development and commercialization rights to the compound CH5126766. The compound is now referred to as VS-6766.

Intermittent schedules of CH5126766, an oral MEK-pan-RAF inhibitor, may be tolerated and effective in solid tumors and multiple myeloma, according to research in The Lancet Oncology.

Previous studies have shown CH5126766 (also known as VS-6766, and previously known as ROS5126766) to have antitumor activity in various solid tumors; however, toxicities limited further development of the drug. The current phase 1 dose-escalation and basket dose-expansion study sought to examine the safety and toxicity of an intermittent dosing schedule.

Mutations in the MAPK pathway have been associated with more than a third of solid tumors and about half of multiple myeloma cases. The study treatment inhibits MEK through the formation of a stable RAF-MEK complex. CH5126766 has a long half-life of approximately 55 hours, suggesting that an intermittent dosing schedule may provide clinically relevant drug exposure.

Continue Reading

The authors enrolled 58 patients with solid tumors or multiple myeloma harboring RAS-RAF-MEK pathway mutations; 29 patients with solid tumors were assigned to the dose-escalation cohort, and 29 were assigned to the basket dose-expansion group (22 patients with solid tumors and 7 patients with multiple myeloma). The patients were administered CH5126766 either 2 or 3 times per week in cycles of 28 days. Treatment continued until disease progression, intolerance, or withdrawal of consent.

The median follow-up duration was 2.3 months. The most common toxicities were rash, creatinine phosphokinase elevation, visual disturbance, diarrhea, and fatigue. At least 1 dose reduction was required in 22 of 57 patients due to treatment-related adverse events. Of the patients who received 4.0 mg twice weekly, 43% (16 of 37 patients) had grade 3 or worse toxicity. 

Of 26 evaluable patients in the basket dose-expansion group, 7 patients had an objective response. In addition, 6 of 20 patients with solid tumors had an objective response, and 1 patient in the dose-escalation group had a partial response. Of the 6 patients with multiple myeloma, 1 patient had a partial response with progression-free survival of 30 weeks, and another patient had durable disease stabilization.

The authors conclude that a dose of 4.0 mg twice per week was well-tolerated. Future studies with larger sample sizes of each tumor type are needed to evaluate the antitumor activity of CH5126766.

Disclosures: Some authors have declared affiliations with or received grant support from the pharmaceutical industry. Please refer to the original study for a full list of disclosures.


Guo C, Chénard-Poirier M, Roda D, et al. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet Oncol. 2020;21(11):1478-1488. doi:10.1016/S1470-2045(20)30464-2

This article originally appeared on Hematology Advisor